United Therapeutics Corp. ( (UTHR) ) has released its Q4 earnings. Here is a breakdown of the information United Therapeutics Corp. presented to its investors.
United Therapeutics Corporation is a public benefit biotechnology company focused on developing pharmaceutical therapies and technologies to enhance the availability of transplantable organs, primarily operating in the healthcare sector. The company has reported a record-breaking revenue of $2.88 billion for the full year 2024, marking a 24% increase from the previous year, driven by strong sales across its product portfolio. Key financial highlights include a significant rise in net income to $1.195 billion and notable growth in sales of Tyvaso DPI and other products. Strategic advancements include the enrollment of TETON studies and FDA clearance for a xenotransplantation study. Looking ahead, United Therapeutics aims to maintain its growth trajectory into 2025, leveraging its robust product lineup and ongoing clinical developments to address unmet medical needs.